Updated: 2012-10-27 18:30:03
It’s no secret that there is a national shortage of psychiatrists. The situation is quite dire, according to the National Institute on Mental Health. In recent years, fewer than 5 percent of medical school students have applied for psychiatry related … Continue reading →
Updated: 2012-10-26 23:43:41
Marin Veldic, M.D., a psychiatrist in the Mayo Clinic Mood Disorders Clinic is doing some very interesting reserach in epigenetics – that is, that study of how environmental factors outside of parents and original genetic code impact/change our genetic predisposition. More specifically, Dr. … Continue reading →
Updated: 2012-10-25 23:24:19
Mayo Clinic researchers are sharing their latest research findings and expertise this week at the American Academy of Child and Adolescent Psychiatry Meeting in San Francisco. The meeting is also a good chance for our physicians to learn about the … Continue reading →
Updated: 2012-10-25 22:46:17
Paul Croarkin, D.O., M.S., hosted a research panel at the American Academy of Childhood and Adolescent Psychiatry meeting in San Franisico this week. He and his fellow presenters are looking for an objective measure to gauge how well chemicals and other therapies are working … Continue reading →
Updated: 2012-10-19 20:23:54
Above Keith Berge, M.D., an Anesthesiologist at Mayo Clinic in Rochester, Minn, reviews an article that appeared in the July 2012 issue of Mayo Clinic Proceedings’ on the increasing occurrence and awareness of drug diversion within the medical community, which … Continue reading →
Updated: 2012-10-18 23:06:26
Today’s patients are educating themselves far beyond traditional waiting room pamphlets. With social media, search engines and active disease communities, engaging with patients in the online space where they’re searching for answers offers physicians a new way to educate their patients. During this week’s … Continue reading →
Updated: 2012-10-15 18:00:00
LYON, France -- Daclizumab, a biologic drug targeting the interleukin-2 pathway, showed sustained efficacy in the second year of a phase II trial in multiple sclerosis, but serious autoimmune issues also emerged.
Updated: 2012-10-15 14:00:00
LYON, France -- High-dose estrogen supplements added to standard interferon-beta therapy in multiple sclerosis could increase treatment responses in at least some women, a researcher said here.
Updated: 2012-10-13 18:30:00
LYON, France -- Multiple sclerosis appears to be joining psoriasis and rheumatoid arthritis as potential indications for the anti-IL-17A agent secukinumab (AIN457), results of a small trial suggested.
Updated: 2012-10-12 16:59:18
LYON, France -- Patients undergoing cranial venoplasty as a multiple sclerosis therapy in Italy rarely showed improvement in objective disease measures, although half said they felt better.
Updated: 2012-10-10 05:10:07
LYON -- High-dose simvastatin (Zocor) significantly reduced brain atrophy and slowed advancement of disability for 2 years in patients with secondary progressive multiple sclerosis, researchers said here.
